Tyra Biosciences, Inc.
TYRA
$10.04
-$0.05-0.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.43% | 25.92% | 34.23% | 27.06% | 9.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.34% | 44.37% | 61.75% | 50.51% | 35.67% |
| Operating Income | -30.34% | -44.37% | -61.75% | -50.51% | -35.67% |
| Income Before Tax | -25.09% | -41.46% | -59.97% | -44.04% | -24.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.09% | -41.46% | -59.97% | -44.04% | -24.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.09% | -41.46% | -59.97% | -44.04% | -24.96% |
| EBIT | -30.34% | -44.37% | -61.75% | -50.51% | -35.67% |
| EBITDA | -30.27% | -44.39% | -61.94% | -50.64% | -35.75% |
| EPS Basic | 6.72% | -15.51% | -41.56% | -35.33% | -22.33% |
| Normalized Basic EPS | 6.73% | -15.50% | -41.55% | -35.35% | -22.34% |
| EPS Diluted | 6.72% | -15.51% | -41.56% | -35.33% | -22.33% |
| Normalized Diluted EPS | 6.73% | -15.50% | -41.55% | -35.35% | -22.34% |
| Average Basic Shares Outstanding | 33.96% | 25.10% | 16.28% | 7.29% | 1.96% |
| Average Diluted Shares Outstanding | 33.96% | 25.10% | 16.28% | 7.29% | 1.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |